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Abstract
Background: Blinding trachoma, caused by the bacteria Chlamydia trachomatis, is a neglected tropical disease
targeted for elimination by 2020. A major component of the elimination strategy is mass drug administration (MDA)
with azithromycin. Currently, program decisions are made based on clinical signs of ocular infection, but we have
been investigating the use of antibody responses for post-MDA surveillance. In a previous study, IgG responses were
detected in children lacking clinical evidence of trachoma, suggesting that IgG responses represented historical
infection. To explore the utility of serology for program evaluation, we compared IgG and IgA responses to
trachoma antigens and examined changes in IgG and IgA post-drug treatment.
Methods: Dried blood spots and ocular swabs were collected with parental consent from 264 1–6 year olds in a
single village of Kongwa District, central Tanzania. Each child also received an ocular exam for detection of clinical
signs of trachoma. MDA was given, and six months later an additional blood spot was taken from these same
children. Ocular swabs were analyzed for C. trachomatis DNA and antibody responses for IgA and total IgG were
measured in dried bloods spots.
Results: Baseline antibody responses showed an increase in antibody levels with age. By age 6, the percentage
positive for IgG (96.0%) was much higher than for IgA (74.2%). Antibody responses to trachoma antigens declined
significantly six months after drug treatment for most age groups. The percentage decrease in IgA response was
much greater than for IgG. However, no instances of seroreversion were observed.
Conclusions: Data presented here suggest that focusing on concordant antibody responses in children will provide
the best serological surveillance strategy for evaluation of trachoma control programs.
Background
Trachoma is a neglected tropical disease caused by the
bacterium Chlamydia trachomatis that is associated with
ocular pathology. Trachoma causes an estimated 3.8 mil-
lion cases of blindness and 5.3 million cases of low vision
[1] in Africa and Southeast Asia. Active infection, defined
as trachomatous inflammation–follicular (TF) or trach-
omatous inflammation–intense (TI), is self-limiting, but
repeated infections can lead to pathology in the form of
scarring (TS); trichiasis (TT), distinguishable by turned-in
eyelashes rubbing against the globe of the eye; and irre-
versible blindness caused by corneal opacity (CO). Global
efforts to eliminate blinding trachoma as a public health
problem by the year 2020 are based on the components of
the SAFE strategy: surgery for treatment of trichiasis, mass
drug administration of antibiotics, and promotion of facial
cleanliness and environmental improvements.
As elimination efforts proceed, defining programmatic
endpoints becomes a priority. We have recently begun
examining the utility of serological tests for monitoring
and evaluation of trachoma elimination programs [2].
Antibody responses to the chlamydial antigens pgp3 and
CT694 show high sensitivity and specificity for trachoma
infection [2]. These studies also showed that a large per-
centage of children have detectable antibody responses,
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but exhibit no clinical signs and lack bacterial DNA in
the conjunctiva, suggesting that these responses are indi-
cators of historical rather than active infection [2].
Exactly how antibody responses can be used within a
programmatic context is still under evaluation. An ideal
test would be able to uniquely detect recent infections
and could be integrated with serological tests for moni-
toring other neglected tropical disease programs or na-
tional surveillance programs [3-5]. The studies described
herein sought to define parameters of anti-chlamydial
antibody responses in a trachoma-endemic area and
how these responses could be utilized in the framework
of monitoring and evaluating trachoma control pro-
grams. To this end we (1) examined IgA responses to
the previously defined antigens pgp3 and CT694 with
the Luminex multiplex bead assay as possible indicators
of recent infection and (2) monitored IgG and IgA re-
sponses in children at baseline and 6 months after MDA




Studies were conducted in the Kongwa District of
Tanzania as part of ongoing clinical trials to evaluate the
impact of alternative models of community-wide treat-
ment with azithromycin and to compare nucleic acid
amplification test methods [6,7]. Children 1–6 years
of age were recruited from a single community to
maximize the number of PCR-positive samples within
the study. After baseline data collection, all participants
(N = 264) received a single oral dose of azithromycin as
part of a mass drug administration (MDA) program. At
baseline, clinical examinations were performed, and
dried blood spots (DBS) and conjunctival eye swabs for
PCR were collected. At 6 months after MDA, only dried
blood spots were collected. A total of 173 children were
examined at both baseline and the six month post-
treatment period, and analysis was limited to this subset
of children. Parents or guardians provided written in-
formed consent for children participating in the study.
The study was approved by The Institutional Review
Board of the Johns Hopkins University School of Medi-
cine (Baltimore, MD) and the Tanzanian National Insti-
tute for Medical Research. Researchers at Centers for
Disease Control and Prevention (Atlanta, GA) received
de-identified samples and were non-engaged.
Grading of ocular Trachoma
Clinical exams, using an expansion of the WHO simpli-
fied grading scheme [8,9] were performed on 264 chil-
dren aged 1 to 6 years who were randomly selected from
a single village in Kongwa District. Trachoma was
graded as zero if the ocular signs did not meet WHO
criteria for TF (trachomatous inflammation: follicular)
or TI (trachomatous inflammation: intense). Grade one
TF or TI met the WHO criteria; grade two for TF was if
there were 10 or more follicles size >0.5 mm in the tarsal
conjunctiva, and TI grade two was present if all the deep
tarsal vessels were obscured by inflammation.
Serology for assessment of Trachoma-specific antibodies
The initial selection, expression, purification, and meth-
odology for IgG antibody detection by Luminex technol-
ogy of the chlamydial recombinant proteins CT694 and
pgp3 antigen are described elsewhere [2]. Briefly, serum
was eluted from dried blood spots and then incubated
with chemically-modified microspheres (Luminex Corp.,
Austin, TX) conjugated to the trachoma antigens pgp3
and CT694. After washing out unbound serum anti-
bodies, bound antibody was detected with biotinylated
mouse anti-human IgG (clone H2; Southern Biotech,
Birmingham, AL) and biotinylated mouse anti-human
IgG4 (clone HP6025; Invitrogen, South San Francisco,
CA), followed by R-phycoerythrin-labeled streptavidin
(SAPE, Invitrogen, South San Francisco, CA). For detec-
tion of IgA antibodies in serum, total IgA was detected
with 50 ng of biotinylated mouse anti-human total IgA
(clone GA112, Zymed Life Technologies, Carlsbad, CA),
followed by SAPE. Beads were suspended in 125 μl PBS,
shaken, and immediately read on a BioPlex 200 instru-
ment (Bio-Rad, Hercules, CA) equipped with Bio-Plex
Manager 6.0 software (Bio-Rad).
Determination of cut-offs for antibody positivity
Receiver operator curves (ROC) were generated for each
antigen to determine cutoff values for IgA responses
using finger prick sera, samples from 122 children from
the United States, and dried blood spots from ten 1–9
year old Tanzanian children with ocular swabs that were
PCR-positive for C. trachomatis DNA. The threshold for
IgA positivity was determined to be a median fluores-
cence intensity minus background (MFI-BG) of 120 for
pgp3 and 43 for CT694. The cutoffs for IgG responses
were the same as previously described [2]; pgp3 had a
cutoff value of 1024 and CT694 had a cutoff of 232.
PCR
Eye swabs were collected for PCR analyses of C. tracho-
matis from all children at the baseline collection, with
careful attention to avoid field contamination. Swabs
were sent to the International Chlamydia Research La-
boratory at Johns Hopkins University and tested for the
presence of chlamydial DNA using Amplicor CT/NG
(Roche, Basel, Switzerland). Details of laboratory pro-
cessing were described elsewhere [6]. According to the
manufacturer’s directions, the Amplicor test was positive
if the optical density read at 450 nM was ≥0.8 and
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negative if the signal was <0.2 and equivocal if in-
between. All equivocal tests were re-tested in duplicate,
and only graded positive if at least one test was positive.
Statistical analysis
Plots and descriptive analyses were conducted using
GraphPad Prism 5.03 (GraphPad Software Inc., La Jolla,
CA). Specificity and sensitivity were calculated for both
antigens by receiver operator characteristic analysis.
Comparisons of serological responses, clinical trachoma,
PCR results for infection, and age groups were calcu-
lated with confidence intervals (CI) of 95% using Mann–
Whitney tests and Wilcoxon matched pairs signed rank
tests to generate p-values.
To assess the difference in mean percentage decreases of
pgp3 and CT694 antigens following drug treatment, a lin-
ear regression model was developed in R version 3.0.1
(R Foundation for Statistical Computing, Vienna, Austria).
Since the correlations between baseline and 6 month pgp3
and CT694 scores were greater than 0.8, we analyzed the
response variable as a percent decrease within the 6 month
time period which is acceptable based on previous research
[10]. Our final models retained the age of the participant in
order to calculate age-specific percent decreases and
Schwarz’s Bayesian information criterion indicated gender
did not improve model fit [11]. Hence, our final models in-
clude age as the only predictor. Results are presented as the
mean percentage decrease of pgp3 and CT694 values
broken down by age. The two-sided tests and confidence
intervals are based on the 5% level of significance.
Results
Comparison of antibody responses, clinical pathology,
and PCR detection of bacterial DNA in the conjunctiva at
baseline
Of DBS collected from 264 total participants, 208 samples
were tested for IgG antibodies at baseline. The remainder
were excluded if samples were collected at only a single
time point from a given individual or if that individual was
<1 year of age, since antibody responses in this age range
may reflect transfer of maternal IgG. From the subset of
208 samples, clinical prevalence of TF/TI was 47%, infec-
tion prevalence by PCR was 25%, and IgG seroprevalence
was 64%. In accordance with previous studies, serology
showed high sensitivity, as 49/51 (96%) of PCR-positive in-
dividuals tested positive for IgG antibodies against pgp3
and CT694 (Figure 1). By age 4, IgG seroprevalence was
81% and by age 6, 97% of participants had IgG responses
against CT694 or pgp3 (Figure 2). The concordance be-
tween pgp3 and CT694 IgG responses was 95.4%(OR =
696.83; 95% CI = 149.02-6691 [12]).
Of the 184 samples that were tested for IgA anti-
bodies, 99 (53.2%) had responses to pgp3, CT694, or
both (Figure 2). Similarly to IgG, an age-specific increase
in IgA responses was also observed (Figure 2). The peak
IgA response was 74.2% among 6 year olds. The con-
cordance between pgp3 and CT694 IgA responses was
81.8% (OR = 167.15; 95% CI = 39.10-1591.26 [12]). The
majority of IgA-positive samples had responses to pgp3
(98/99) whereas fewer had responses to CT694 (82/99).
Only one CT694 IgA + sample did not have a pgp3 IgA
response. While 48/50 PCR-positive samples tested positive
for IgA antibody against pgp3, only 46/50 PCR-positive
samples (92%) were positive for CT694 IgA antibodies.
The median IgA antibody response for children with
normal ocular findings (a TF/TI score of zero) was
significantly lower than those with observed ocular dis-
ease (a TF/TI score of two) for both pgp3 and CT694
(p < 0.001 for each antigen, Figure 1).
Comparison of IgG and IgA responses on the 184
samples for which both responses were measured
showed that of those samples with IgG responses to ei-
ther antigen (n = 122, 66%) , 21 (17%) were seronegative
to both antigens for IgA, 23 (19%) were seronegative for
pgp3 IgA, and 40 (33%) were seronegative for CT694
IgA. All IgA-positive samples had positive IgG re-
sponses; one IgA positive sample was positive for only
IgG pgp3, while the rest were IgG positive to both anti-
gens (data not shown).
No gender association in IgA or IgG response was ob-
served (data not shown).
Kinetics of IgG and IgA responses after drug treatment
Antibody responses in individuals at baseline and six
months were compared in all individuals with a positive
antibody response at baseline. IgG and IgA responses
decreased for both pgp3 and CT694 when comparing
paired baseline and six month post-treatment responses
stratified by age (Figure 3). All age groups showed sig-
nificant decreases in antibody responses from baseline to
six months post treatment for both antigens, with the
exception of 2 year old children, and 3 year old children
for CT694 (Table 1).
At six months post-treatment, IgA responses de-
creased across all ages for both pgp3 and CT694
(Figure 3). While responses decreased, no children
reverted to seronegative status. The mean decline in
antibody for antibody-positive children decreased with
age. The greatest decline for pgp3 IgA responses was
seen in the one-year-old children, while the mean de-
cline was smaller in the six-year-old children (decline =
325.2 (60.08%) for one-year-old children, and 145.9
(52.53%) for six-year-old children). A similar trend in
the decline of the antibody response was seen in CT694
among antibody positive individuals (decline = 35.85
(75.06%) for one-year-old children and change = 31.34
(53.01%) for six-year-old children).
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Discussion
Seroprevalence has the potential to be useful for decision-
making at multiple stages of trachoma control programs,
from mapping to stopping MDA to long-term monitoring
and evaluation. We are focusing on serological testing in
terms of making decisions to cease MDA and long-term
surveillance, since recent funding from the Department
for International Development (DFID) in the United
Kingdom to map over 1200 districts in over 30 countries
suspected to be trachoma-endemic (www.sightsavers.org)
IgG







































Figure 2 Age prevalence curve of IgG and IgA responses at baseline. DBS were collected from participants and analyzed for IgG and IgA
levels by Luminex multiplex assay. Seroprevalence (% antibody positive/total) was plotted against age. Blue closed circles show% positive to both
pgp3 and CT694 antigens; green open circles show% positive to pgp3 but not CT694; purple open circles show% positive to CT694 but not
pgp3; and red closed circles show% positive to any antigen.
Figure 1 Antibody response by clinical diagnosis and PCR. Median responses are shown in median fluorescence intensity minus background
(MFI-BG) for antibody response to pgp3 (left) and CT694 (right) in relation to clinical diagnosis. Antibody response to pgp3 and CT694 is shown
by PCR positivity to the right of each graph. Responses shown in red indicate PCR positivity. IgG responses (top panels) and IgA responses
(bottom panel) are shown. For IgG, N = 208 and for IgA, N = 184.
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makes the validation of serological tools for mapping a
low priority. The program end-point is not the interrup-
tion of trachoma transmission, but the elimination of
blinding trachoma as a public health problem [13]. Recru-
descence of the disease long-term is still possible given
the right conditions; therefore long-term monitoring strat-
egies that can be easily integrated into ongoing national
surveillance systems for disease and/or vaccine coverage
offer the best option for surveillance once the currently
defined end-points have been met and elimination pro-
grams have ceased.
In previous studies [2], IgG responses to C. trachoma-
tis antigens were measured in children following mul-
tiple rounds of MDA. IgG responses correlated with
ocular pathology and infection status, but also increased
with age, making it difficult to determine if serological
responses were due to an active or previous infection or
to assess the impact of multiple rounds of MDA. The
study reported here provides a first look at antibody
responses in a high prevalence community before MDA.
Baseline analysis showed good correlation between IgG
responses, increasing TF/TI score, and PCR-positive
specimens. In areas of high TF prevalence, IgG serology
shows that well over 1/3 of children age 3 and under
have been exposed to trachoma antigens, while almost
100% of children age 6 have been exposed. Analysis of
IgG responses 6 months after MDA showed a significant
decrease in antibody levels (represented here by MFI) in
all age groups, but no instances of seroreversion, within
6 months following treatment. The lack of a significant
decline in IgG responses is likely due to the presence of
long-lived memory B cells or plasma cells induced by
multiple exposures to ocular chlamydia experienced by
children in endemic regions [14]. One could hypothesize
from the data that the steeper decline in IgG responses
after treatment in younger children is related to a lower
overall antigen load experienced as a result of fewer
exposures, and that an increase in the number of

























































Figure 3 Difference in individual IgG and IgA responses by age 6 months post-drug treatment. DBS were taken prior to drug treatment
with azithromycin and 6 months afterwards. IgG and IgA levels were measured by Luminex multiplex assay and data from paired samples were
plotted using GraphPad Prism. Lines connect paired samples from the same individual.
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exposures over time repeatedly boosts memory B cells
and plasma cells to become long-lived. Data from mur-
ine models [15,16], vaccination for smallpox [17-19] and
other viral infections [20], and examination of humoral
responses from 1918 influenza pandemic survivors nine
decades later [21] have all shown that plasma cells can
be incredibly long-lived, being present decades after the
initial stimuli. However, it is possible that the local
rather than systemic nature of ocular chlamydia infecti-
on requires multiple exposures to generate long-lived
plasma cells to maintain high levels of circulating
antibody.
IgA responses were also examined to determine if mu-
cosal responses may be a better indicator of recent infec-
tion, as reported for Campylobacter infection [22,23].
Fewer children in this study had IgA responses than IgG
responses, although this difference was more pro-
nounced in older age groups. Virtually the same percent-
age of 1–3 year olds had IgG and IgA responses (39.4 vs.
36.1%, respectively), while fewer 4–6 year olds had IgA
responses (86.4% IgG + compared to 64.1% IgA+). The
MFI for positive IgA samples was overall about 1–1.5
log fold lower than for positive IgG responses, which is
to be expected based on the overall lower IgA titers in
serum than IgG [24,25]. IgA responses are related to the
total antigen dose, whether a large bolus or repeated in-
fections [26], so the lower percentage of children sero-
prevalent for IgA may represent a lower antigen load
and failure to seroconvert to IgA positivity. Following
drug treatment, IgA levels decreased at each age group
more so than the corresponding IgG responses. In chil-
dren between the ages of two and five, the decrease in
IgA responses to CT694 were not as significant as other
age groups, and low samples sizes may have contributed
to the variance in slopes for these groups. The large vari-
ance in responses, in conjunction with a low sample size,
does not produce an ideal normal distribution to com-
pare the mean antibody responses from baseline to six
months post treatment (data of remaining slopes not
shown). While IgA responses can be long-lived, IgA
levels will decline following exposure to other mucosal
organisms [26], which may also contribute to the low
IgA titers, seroprevalence, and more significant post-
treatment decline than IgG.
The use of IgA analysis in a programmatic context
poses some problems. IgA is the most prevalent isotype
in mucosal surfaces but is a minor antibody isotype in
the blood, which will be the sample type almost certainly
used for large scale monitoring and evaluation of trach-
oma control programs. From a technical standpoint,
testing for IgA poses additional problems for high
through-put surveillance of large populations. IgG deple-
tions prior to IgA analysis is recommended due to the
lower serum concentrations of IgA than IgG [24,25] and
this additional step adds significantly to time and costs.
Testing for IgA also negates the ability to multiplex with
IgG responses of other disease antigens. IgM may be a
better option for picking up recent infections, but the
same obstacles to using this in a high-throughput, inte-
grated platform as IgA remain. From a technical stand-
point, IgA assays in this study had higher CVs than IgG
assays did, with almost a quarter of the samples having
CVs of greater than 15% for one or both antigen(s). This
is likely due to the low concentration of IgA in the
Table 1 Decrease in antibody level 6 months after drug treatment stratified by age
Age (years) N % pgp3 Ab + after 6 mos (CI) P-value N % CT694 Ab + after 6 mos (CI) P-value
IgG 0.06 0.28
1 8 22.24 (4.24, 40.25) 0.01 8 36.89 (10.46, 63.32) 0.002
2 5 9.64 (−13.14, 32.41) 0.83 6 32.25 (1.73, 62.77) 0.03
3 14 4.94 (−8.67, 18.54) 0.91 15 18.36 (−0.94, 37.67) 0.07
4 22 9.07 (−1.79, 19.93) 0.15 23 15.59 (0.00, 31.18) 0.05
5 30 12.01 (2.72, 21.31) 0.005 28 16.40 (2.27, 30.53) 0.01
6 26 4.01 (−5.98, 14.00) 0.86 25 0.60 (−14.36, 15.55) 1.00
IgA 0.003 0.0006
1 7 60.08 (31.36, 88.80) <0.0001 6 75.06 (40.00, 100.00) <0.0001
2 5 60.11 (26.12, 94.10) <0.0001 4 68.85 (25.90, 100.00) 0.0003
3 12 47.91 (25.97, 69.85) <0.0001 10 34.25 (7.08, 61.41) 0.01
4 14 41.91 (21.60, 62.22) <0.0001 11 30.93 (5.03, 56.83) 0.01
5 23 45.52 (29.67, 61.37) <0.0001 20 53.66 (34.45, 72.87) <0.0001
6 20 52.53 (35.53, 69.52) <0.0001 17 53.01 (32.17, 73.84) <0.0001
Values show the mean percentage drop in antibody median fluorescence intensity-background (MFI-BG) for IgG (top section) and IgA (bottom) from baseline to
6 months after drug treatment in paired samples. 95% confident intervals are shown in parentheses. P values testing for a difference from zero (no change)
of < 0.05 were considered significant. P values in bold test for an average difference from zero across all age groups.
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serum [26] and possibly through the binding of the more
abundant IgG to antigen, sterically hindering the binding
of IgA in the assay. This unexpected technical difficulty
represents an additional obstacle to using IgA serology
on a broad platform for monitoring and evaluating
trachoma programs.
Conclusions
The lack of seroreversion 6 months after drug treatment
shown in this study confirms that surveillance will need
to focus on very young children born after MDA cessa-
tion. It is possible that 6 months is too short a time
frame to detect seroreversion; that this may occur after
interruption of transmission and studies are underway to
address this. Even in the absence of seroreversion post-
treatment, the absence of antibody responses among
young children will be a strong indicator of program im-
pact. Despite the large differences in the odds ratios, the
overlapping CIs indicate no significant differences in the
agreement between the IgG and IgA responses to the
two antigens. A larger sample size will provide definitive
information to determine if looking at only concordant
responses in the assay will provide the best estimate of
transmission. Data provided herein and in ongoing stud-
ies will help inform the best strategy for employing
trachoma serology for post-MDA surveillance.
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